Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Status:
Completed
Trial end date:
2019-07-16
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of panobinostat and everolimus
when given together and to see how well they work in treating patients with multiple myeloma,
non-Hodgkin lymphoma, or Hodgkin lymphoma that has come back. Panobinostat and everolimus may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.